JP2023533204A5 - - Google Patents
Info
- Publication number
- JP2023533204A5 JP2023533204A5 JP2022580102A JP2022580102A JP2023533204A5 JP 2023533204 A5 JP2023533204 A5 JP 2023533204A5 JP 2022580102 A JP2022580102 A JP 2022580102A JP 2022580102 A JP2022580102 A JP 2022580102A JP 2023533204 A5 JP2023533204 A5 JP 2023533204A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- composition according
- encoded
- gene
- her2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044675P | 2020-06-26 | 2020-06-26 | |
| US63/044,675 | 2020-06-26 | ||
| PCT/US2021/039046 WO2021263081A2 (en) | 2020-06-26 | 2021-06-25 | Breast cancer vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533204A JP2023533204A (ja) | 2023-08-02 |
| JP2023533204A5 true JP2023533204A5 (enExample) | 2024-07-02 |
Family
ID=79281909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580102A Pending JP2023533204A (ja) | 2020-06-26 | 2021-06-25 | 乳がんワクチン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230233656A1 (enExample) |
| EP (1) | EP4171619A4 (enExample) |
| JP (1) | JP2023533204A (enExample) |
| AU (1) | AU2021294322A1 (enExample) |
| CA (1) | CA3183774A1 (enExample) |
| WO (1) | WO2021263081A2 (enExample) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1748067A1 (en) * | 2005-07-29 | 2007-01-31 | Institut Pasteur | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes |
| WO2009046738A1 (en) * | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| WO2010037408A1 (en) * | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| ES2771862T3 (es) * | 2013-10-28 | 2020-07-07 | Invectys | Una vacuna de ADN que codifica telomerasa |
| US20180133327A1 (en) * | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| EP3297658A1 (en) * | 2015-05-18 | 2018-03-28 | OncoQR ML GmbH | Her2/neu immunogenic composition |
| WO2017152042A2 (en) * | 2016-03-04 | 2017-09-08 | New York University | Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity |
| CA3026345A1 (en) * | 2016-06-03 | 2017-12-07 | Etubics Corporation | Compositions and methods for tumor vaccination and immunotherapy involving her2/neu |
| US12390514B2 (en) * | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| KR20200027551A (ko) * | 2017-07-11 | 2020-03-12 | 화이자 인코포레이티드 | Cea muc1 및 tert를 포함하는 면역원성 조성물 |
| CN111050790B (zh) * | 2017-08-24 | 2024-07-12 | 巴法里安诺迪克有限公司 | 通过静脉内施用重组mva和抗体治疗癌症的组合疗法 |
| CN110790840A (zh) * | 2018-08-01 | 2020-02-14 | 三生国健药业（上海）股份有限公司 | 结合人her2的抗体、其制备方法和用途 |
-
2021
- 2021-06-25 CA CA3183774A patent/CA3183774A1/en active Pending
- 2021-06-25 US US18/012,432 patent/US20230233656A1/en active Pending
- 2021-06-25 AU AU2021294322A patent/AU2021294322A1/en active Pending
- 2021-06-25 EP EP21828216.8A patent/EP4171619A4/en active Pending
- 2021-06-25 JP JP2022580102A patent/JP2023533204A/ja active Pending
- 2021-06-25 WO PCT/US2021/039046 patent/WO2021263081A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12521431B2 (en) | HBV vaccine | |
| CN104271748B9 (zh) | 表达异源肿瘤相关抗原的腺病毒 | |
| Hanke et al. | Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime | |
| US11471527B2 (en) | Virus-like particles including HBs-L antigen protein for causing immune response against HBV | |
| CA2293692A1 (en) | Methods and reagents for vaccination which generate a cd8 t cell immune response | |
| JP2023524916A (ja) | 腫瘍溶解性ウイルスと免疫チェックポイント阻害剤の併用による腫瘍治療 | |
| WO2015106697A1 (zh) | 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗 | |
| CA2297786A1 (en) | New immunoprotective influenza antigen and its use in vaccination | |
| CA2325566A1 (en) | Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates | |
| Kameshima et al. | Immunogenic enhancement and clinical effect by type‐I interferon of anti‐apoptotic protein, survivin‐derived peptide vaccine, in advanced colorectal cancer patients | |
| JPS6349077A (ja) | ベクターウイルスおよびベクターウイルスを含む薬用組成物 | |
| CA2431188A1 (en) | Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens | |
| CN115820696A (zh) | 治疗性多价HPV mRNA疫苗及其制备方法 | |
| WO2023051701A1 (zh) | 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗 | |
| Groeneveldt et al. | Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy | |
| WO2024188144A1 (zh) | 痘病毒mRNA疫苗及用途 | |
| JP2002534481A5 (enExample) | ||
| Ozkan | How close are we to a COVID-19 vaccine | |
| JP2023533204A5 (enExample) | ||
| Bolhassani et al. | Small heat shock proteins B1 and B6: Which one is the most effective adjuvant in therapeutic HPV vaccine? | |
| CN101015689A (zh) | 基于血管紧张素ⅱ的肿瘤多肽疫苗 | |
| US20220152168A1 (en) | Sequential heterologous boost oncolytic viral immunotherapy | |
| WO2018088509A1 (ja) | マラリアワクチン | |
| JP7045024B2 (ja) | マラリアワクチン | |
| CN1517437B (zh) | 特异性治疗肿瘤或胞内感染的疫苗及应用 |